Magazine Article | July 1, 2015

Tonix Pharmaceuticals: Pain Control For PTSD And Fibromyalgia

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Restorative Sleep and a Second Pathway to Pain Control

SNAPSHOT
Tonix Pharmaceuticals has two development programs underway for one drug, TNX-102 SL (cyclobenzaprine), the first in Phase 3 for fibromyalgia; the second, Phase 2 for post-traumatic stress disorder (PTSD). Both programs aim to use an increase in “restorative sleep” as “a means to broadly improve the patient’s symptoms,” including pain. A third development program, with TNX-201 (dexisometheptene mucate) for episodic tension-type headache is due to launch a Phase 2 trial in June 2015.